



TargED Biopharmaceuticals Appoints Dr. Anja Harmeier as Supervisory Board Member

September 5th, 2023

Utrecht, The Netherlands

TargED Biopharmaceuticals is pleased to announce the appointment of Dr. Anja Harmeier as member of its Supervisory Board. Dr. Harmeier, Chief Executive Officer of Rewind Therapeutics, brings extensive experience in biopharmaceutical research and development, particularly in neurodegenerative diseases.

"We are delighted to welcome Dr. Anja Harmeier to our Supervisory Board," said Kristof Vercruyssen, CEO of TargED Biopharmaceuticals. "With a Ph.D. and an MBA, Dr. Harmeier possesses a valuable combination of scientific expertise and business acumen. Her leadership skills and strategic vision have been instrumental in driving the development of novel drug candidates and establishing productive collaborations within the industry. We are confident that her insights and guidance contribute to pursue our mission of improving patient outcomes."

Throughout her career, Dr. Harmeier has made significant contributions to the biopharmaceutical field. Her expertise spans from early-stage research to clinical development, and she has successfully navigated complex tasks while building strong relationships with key stakeholders. Dr. Harmeier started her career at F. Hoffman-La Roche Ltd where she held progressively more responsible positions in preclinical research and early development across various fields, including neuroscience, metabolic diseases, hematological conditions, and rare diseases. Dr. Harmeier later transitioned to the Roche Venture fund, where she served as a director responsible for sourcing, leading, and managing investments like Black Diamond (IPO), Zikani (merger with Eloxx Pharmaceuticals), Vivet, Entrada (IPO), and NMD. Prior to her current role as CEO of Rewind Therapeutics, Dr. Harmeier was a Partner at Pureos Bioventures where she made investments in innovative life sciences companies in the US and Europe including Vico Therapeutics, Corlieve Therapeutics (acquired by UniQure) and River Renal 2/3, as well as fund raising. Dr. Harmeier earned her PhD from the Free University of Berlin in Biochemistry and holds an MBA from Instituto Empresa (IE) in Madrid.

"I am honored to join the Supervisory Board of TargED Biopharmaceuticals," said Dr. Harmeier. "The company's dedication to advancing innovative therapies aligns perfectly with my own passion for improving patient lives. I look forward to leveraging my experience and collaborating with the board and management team to drive strategic growth and contribute to TargED's success." TargED Biopharmaceuticals is confident that Dr. Anja Harmeier's appointment will play a crucial role in shaping the company's future, advancing its mission, and delivering their innovative therapy to patients worldwide.

About TargED Biopharmaceuticals B.V.

TargED Biopharmaceuticals B.V. is a biotechnology company and spin-off of the University Medical Center Utrecht, that develops first-in-class biological drugs to improve treatment of thrombosis. TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies ("VhH") to deliver enzymes to sites of thrombosis, enabling 'targeted' thrombolysis. The lead compound is Microlyse, which is currently under development for thrombotic thrombocytopenic purpura (TTP) and Acute Ischemic Stroke (AIS). The objective is to accelerate thrombolysis in all forms of thrombosis, irrespective of the thrombus composition.

Contact: info@targedbio.com